Association of Esophageal Adenocarcinoma With Β-catenin

Background-Aims: Esophageal cancer is the ninth most prevalent cancer and the sixth leading cause of cancer-related deaths globally. The development of esophageal adenocarcinoma is strongly linked to the expression of β-catenin and E-cadherin. The primary goal of this study is to explore the relationship between esophageal adenocarcinoma and β-catenin. The expression levels of β-catenin and E-cadherin could serve as valuable biomarkers for diagnosing and treating esophageal adenocarcinoma, potentially enhancing patient outcomes Methodology: In this particular quantitative research, a total sampling of the eligible anonymous esophagectomy specimens from 71 patients with esophageal adenocarcinoma was studied to investigate the association of esophageal adenocarcinoma with β-catenin Results: The coefficient of the variable had a positive sign, which implied that the percentage of the existence of β-Catenin Immunohistochemistry tended to increase with the increase in the percentage of E-Cadherin Immunohistochemistry. Also, it could be concluded that gender substantially did not affect the response rate. Conclusions: Targeting the concurrent regulation of β-catenin and E-cadherin could offer a promising therapeutic approach for treating adenocarcinoma. This is because the simultaneous dysfunction of these proteins, hyperactivation of β-catenin and the loss of E-cadherin, are key factors driving the aggressiveness and metastasis of adenocarcinoma.